WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.
- DOI
- 10.1016/j.jaad.2018.01.028
- Published
- 2018 Jan 31
- Container
- Journal of the American Academy of Dermatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- serious concernRetraction Watch retraction: 1 retraction notice matched this DOI.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jaad.2018.01.028,
title = {WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0\% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.},
author = {Stein-Gold L and Kircik LH and Draelos ZD and Werschler P and DuBois J and Lain E and Baumann L and Goldberg DJ and Kaufman J and Tanghetti EA and Alvandi N and Weng E and Berk DR and Ahluwalia G},
year = {2018},
journal = {Journal of the American Academy of Dermatology},
doi = {10.1016/j.jaad.2018.01.028},
url = {https://doi.org/10.1016/j.jaad.2018.01.028}
}RIS
TY - JOUR TI - WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials. AU - Stein-Gold L AU - Kircik LH AU - Draelos ZD AU - Werschler P AU - DuBois J AU - Lain E AU - Baumann L AU - Goldberg DJ AU - Kaufman J AU - Tanghetti EA AU - Alvandi N AU - Weng E AU - Berk DR AU - Ahluwalia G PY - 2018 JO - Journal of the American Academy of Dermatology DO - 10.1016/j.jaad.2018.01.028 UR - https://doi.org/10.1016/j.jaad.2018.01.028 ER -
APA
L, S., LH, K., ZD, D., P, W., J, D., E, L., L, B., DJ, G., J, K., EA, T., N, A., E, W., DR, B., & G, A. (2018). WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2018.01.028
Source records
- pubmed · retrieved 2026-09-24T23:46:00.277Z